Lucid Diagnostics to Present at Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum

Rhea-AI Summary

Lucid Diagnostics Inc. (Nasdaq: LUCD), a cancer prevention medical diagnostics company, announced that CFO Dennis McGrath will present a corporate update at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum on November 18, 2021, at 4:00 PM EST. Lucid focuses on gastroesophageal disease patients at risk of esophageal cancer, offering the EsoGuard Esophageal DNA Test alongside the EsoCheck device. Both are aimed at early cancer detection, with EsoGuard currently marketed as a Laboratory Developed Test in the U.S.

NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that Dennis McGrath, Chief Financial Officer, will present a corporate update at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum on November 18, 2021, at 4:00 PM EST. For more information on the conference, visit https://www.canaccordgenuity.com/capital-markets/about-us/events/.

About Lucid Diagnostics

Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid’s EsoGuard^® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck^® Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable of serving as a widespread screening tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk GERD patients. EsoGuard is commercialized in the U.S. as a Laboratory Developed Test (LDT). EsoCheck is commercialized in the U.S. as a 510(k)-cleared esophageal cell collection device. EsoGuard, used with EsoCheck, was granted FDA Breakthrough Device designation and is the subject of two large, actively enrolling, international multicenter clinical trials to support FDA PMA approval. Lucid is building a network of Lucid Test Centers where at-risk GERD patients can undergo the EsoCheck procedure for EsoGuard testing.

Forward-Looking Statements

This press release includes forward-looking statements. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid’s management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid’s common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid’s products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid’s clinical and preclinical studies; whether and when Lucid’s products are cleared by regulatory authorities; market acceptance of Lucid’s products once cleared and commercialized; Lucid’s ability to raise additional funding as needed; and other competitive developments. In addition, Lucid has been monitoring the COVID-19 pandemic and the pandemic’s impact on Lucid’s businesses. Lucid expects the significance of the COVID-19 pandemic, including the extent of its effect on its financial and operational results, to be dictated by, among other things, the success of efforts to contain the pandemic and the impact of such efforts on Lucid’s businesses. All of these factors are difficult or impossible to predict accurately and many of them are beyond Lucid’s control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid’s future operations, see Lucid’s Registration Statement No. 333-259721 filed with the Securities and Exchange Commission. Lucid disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211117005504/en/

Investors

Lisa DeScenza

LaVoieHealthScience

(617) 351-0243

ldescenza@lavoiehealthscience.com

Media

Kristi Bruno

LaVoieHealthScience

(617) 865-3940

PAVmed@lavoiehealthscience.com

Source: Lucid Diagnostics Inc. PAVmed Inc.

FAQ

What is the purpose of Lucid Diagnostics' presentation on November 18, 2021?

Lucid Diagnostics' CFO Dennis McGrath will present a corporate update, discussing the company's progress and focus on cancer prevention.

What is the significance of the EsoGuard Esophageal DNA Test?

EsoGuard is the first commercially available test designed for early detection of esophageal precancer in patients with GERD, helping to prevent cancer and save lives.

What regulatory approvals does EsoGuard have?

EsoGuard was granted FDA Breakthrough Device designation and is currently subject to clinical trials for FDA PMA approval.

How does the EsoCheck device work?

EsoCheck is a 510(k)-cleared esophageal cell collection device used to collect samples for the EsoGuard test in a noninvasive manner.

What is the relationship between Lucid Diagnostics and PAVmed Inc.?

Lucid Diagnostics is a majority-owned subsidiary of PAVmed Inc., which focuses on innovative medical solutions.